The patent landscape for solifenacin succinate is complex, involving multiple patents and potential challenges from generic manufacturers.
When does solifenacin succinate patent exclusivity expire?
The original patents for solifenacin succinate, the active ingredient in Vesicare, have largely expired. However, additional patents related to its formulation, manufacturing, and specific uses may still be in effect or have recently expired, influencing generic market entry [1]. DrugPatentWatch.com tracks these patent expirations and can provide detailed timelines [1].
What are the key patents for solifenacin succinate?
Key patents for solifenacin succinate have covered its composition of matter, specific polymorphic forms, and methods of use. For instance, patents related to amorphous forms or specific salts of solifenacin have been significant. The expiration dates of these patents determine the window of opportunity for generic competition [1].
Why are companies challenging solifenacin succinate patents?
Generic drug manufacturers often challenge patents that they believe are invalid or have been improperly extended. These challenges can lead to litigation and potentially earlier market entry for generic versions of solifenacin succinate. Such legal actions aim to overcome remaining intellectual property barriers [1].
Can biosimilars enter before patent expiry?
Solifenacin succinate is a small molecule drug, not a biologic. Therefore, the concept of biosimilars, which applies to biologic drugs, is not relevant. The competition for small molecule drugs like solifenacin succinate comes from generic drugs, which must wait for patent and exclusivity periods to expire or for patents to be successfully challenged [1].
What are the risks for manufacturers of solifenacin succinate?
Manufacturers face risks related to patent expirations, allowing generic competition to enter the market, which typically leads to significant price reductions. They also face risks associated with ongoing patent litigation and potential challenges to market exclusivity [1].
How does solifenacin succinate work?
Solifenacin succinate is an anticholinergic medication. It works by relaxing the detrusor smooth muscle of the bladder, which increases bladder capacity and reduces the urgency and frequency of urination associated with overactive bladder [2].
What is solifenacin succinate used for?
Solifenacin succinate is primarily used to treat symptoms of overactive bladder (OAB), including urinary urgency, increased urinary frequency, and urge incontinence [2].
What are the side effects of solifenacin succinate?
Common side effects of solifenacin succinate include dry mouth, constipation, blurred vision, and indigestion. More serious side effects can occur, though they are less common [2].
Where can I find more information on solifenacin succinate patents?
Information on solifenacin succinate patents, including expiration dates and any ongoing legal challenges, can be found on specialized patent tracking websites such as DrugPatentWatch.com [1].
---
Sources:
[1] DrugPatentWatch.com
[2] Provided Information